Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
M Tiseo, G Rossi, M Capelletti, G Sartori, E Spiritelli… - Lung cancer, 2010 - Elsevier
A number of different clinical characteristics and molecular markers related to epidermal
growth factor receptor (EGFR) activation have been reported to singly correlate with …
growth factor receptor (EGFR) activation have been reported to singly correlate with …
Spotlight on gefitinib in non-small-cell lung cancer
JE Frampton, SE Easthope - American Journal of Pharmacogenomics, 2005 - Springer
Gefitinib (Iressa™), the first commercially available epidermal growth factor receptor-tyrosine
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …
kinase (EGFR-TK) inhibitor, is indicated in the management of patients with locally …
[HTML][HTML] Tentative identification of gefitinib metabolites in non-small-cell lung cancer patient plasma using ultra-performance liquid chromatography coupled with triple …
C Wang, J Zhang, S Zhou, L Yu, F Han, R Ling, J Ling - PLoS One, 2020 - journals.plos.org
Background Gefitinib is an orally potent and selective ATP-competitive inhibitor of epidermal
growth factor receptor (EGFR) tyrosine kinase and is commonly used to treat locally …
growth factor receptor (EGFR) tyrosine kinase and is commonly used to treat locally …
[HTML][HTML] Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
L Kim, M Saieg, M Di Maio, C Gallo, C Butts… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background The TORCH phase III trial compared the efficacy of first-line erlotinib followed
by chemotherapy at progression (experimental arm) with the reverse sequence (standard …
by chemotherapy at progression (experimental arm) with the reverse sequence (standard …
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations
K Mizoguchi, Y Nakamura, K Sano, S Sato… - Cancer chemotherapy …, 2016 - Springer
Purpose The relationship between plasma concentration and antitumor activity of gefitinib
was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring …
was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring …
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
Abstract The− 216G/T,− 191C/A, intron 1 and Arg497Lys epidermal growth factor receptor
(EGFR) polymorphisms were evaluated in 92 advanced non-small-cell lung cancer patients …
(EGFR) polymorphisms were evaluated in 92 advanced non-small-cell lung cancer patients …
Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC–MS/MS and its application to a pharmacokinetics study
N Zheng, C Zhao, XR He, ST Jiang, SY Han… - … of Chromatography B, 2016 - Elsevier
Gefitinib (Iressa) is the first oral EGFR tyrosine kinase inhibitor and it brings benefits to non-
small cell lung cancer patients with EGFR mutation. In this study, a simple, rapid and …
small cell lung cancer patients with EGFR mutation. In this study, a simple, rapid and …
Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non–small-cell lung cancer
H Yokota, K Sato, Y Okuda, H Kobayashi, M Takeda… - Clinical lung cancer, 2017 - Elsevier
Introduction In this study, we investigated the degree of drug interactions between gefitinib
and gastric acid suppressants (ie, histamine 2-receptor antagonists [H2RAs] or proton pump …
and gastric acid suppressants (ie, histamine 2-receptor antagonists [H2RAs] or proton pump …
Defining gefitinib sensitivity/resistance in non-small cell lung cancer (NSCLC) cell lines by affymetrix gene arrays
FR Hirsch, WA Franklin, SE Witta, B Helfrich… - Journal of Clinical …, 2004 - ascopubs.org
7027 Background: Gefitinib (Iressa) and other EGFR inhibitors are active in 12–19% of
NSCLC patients previously treated with chemotherapy. Currently, there are no selection …
NSCLC patients previously treated with chemotherapy. Currently, there are no selection …
[HTML][HTML] How molecular understanding affects to prescribing patterns and clinical outcome of gefitinib in non-small cell lung cancer? 10 year experience of single …
Purpose Gefitinib was introduced in 2002 for treatment of non-small cell lung cancer
(NSCLC); however, it is not clear whether its use in daily practice has changed the outcome …
(NSCLC); however, it is not clear whether its use in daily practice has changed the outcome …